Chronic Kidney Disease Anemia: Opportunity Assessment and Forecast
Summary
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the CKD Anemia market through 2034.
There will be an overall increase in the diagnosed prevalent cases of CKD Anemia in the 7MM across the forecast period.
Across the 7MM, the mainstay treatment for CKD Anemia involves the use of ESAs and iron therapies.
Significant clinical and environmental unmet needs remain in the CKD Anemia market.
The late-stage CKD anemia pipeline consists of 2 agents.
The CKD Anemia market in the 7MM was valued at $4.4 billion in 2024. The market is projected to grow at a CAGR of 1.7%, reaching $5.3 billion by 2034.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook